$QURE
uniQure N.V.

2022 Q1 Form 10-Q Financial Statement

#000155837022006570 Filed on May 02, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $1.792M $454.0K
YoY Change 294.71% 336.54%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.99M $12.38M
YoY Change -11.22% 36.41%
% of Gross Profit
Research & Development $45.00M $32.66M
YoY Change 37.81% 25.54%
% of Gross Profit
Depreciation & Amortization $2.122M $1.860M
YoY Change 14.09% 7.51%
% of Gross Profit
Operating Expenses $55.99M $45.03M
YoY Change 24.34% 28.35%
Operating Profit -$54.08M -$44.46M
YoY Change 21.64% 29.0%
Interest Expense $2.515M $1.551M
YoY Change 62.15% 59.08%
% of Operating Profit
Other Income/Expense, Net $193.0K $233.0K
YoY Change -17.17% -31.27%
Pretax Income -$47.29M -$41.34M
YoY Change 14.39% 47.66%
Income Tax -$616.0K $213.0K
% Of Pretax Income
Net Earnings -$46.68M -$41.56M
YoY Change 12.33% 48.42%
Net Earnings / Revenue -2604.8% -9153.3%
Basic Earnings Per Share -$1.00 -$0.91
Diluted Earnings Per Share -$1.00 -$0.91
COMMON SHARES
Basic Shares Outstanding 46.60M 45.47M
Diluted Shares Outstanding 46.60M 45.47M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $524.9M $260.8M
YoY Change 101.26% -23.74%
Cash & Equivalents $524.9M $260.8M
Short-Term Investments
Other Short-Term Assets $14.68M $6.886M
YoY Change 113.22% 336.93%
Inventory
Prepaid Expenses $12.42M $9.186M
Receivables $38.64M $5.445M
Other Receivables $0.00 $0.00
Total Short-Term Assets $578.2M $282.3M
YoY Change 104.8% -19.24%
LONG-TERM ASSETS
Property, Plant & Equipment $44.92M $33.86M
YoY Change 32.65% 22.09%
Goodwill $26.57M $518.0K
YoY Change 5028.38% 6.58%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.937M $18.90M
YoY Change -68.59% 551.72%
Total Long-Term Assets $178.9M $81.52M
YoY Change 119.49% 26.11%
TOTAL ASSETS
Total Short-Term Assets $578.2M $282.3M
Total Long-Term Assets $178.9M $81.52M
Total Assets $757.2M $363.9M
YoY Change 108.09% -12.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.920M $5.749M
YoY Change 72.55% 15.23%
Accrued Expenses $19.95M $20.90M
YoY Change -4.55% 119.8%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $44.70M $32.10M
YoY Change 39.24% 18.34%
LONG-TERM LIABILITIES
Long-Term Debt $101.4M $70.47M
YoY Change 43.93% 94.61%
Other Long-Term Liabilities $3.439M $3.107M
YoY Change 10.69% 492.94%
Total Long-Term Liabilities $166.4M $103.1M
YoY Change 61.51% 12.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $44.70M $32.10M
Total Long-Term Liabilities $166.4M $103.1M
Total Liabilities $211.1M $135.2M
YoY Change 56.22% 13.49%
SHAREHOLDERS EQUITY
Retained Earnings -$501.8M -$826.3M
YoY Change -39.27% 20.15%
Common Stock $2.821M $2.780M
YoY Change 1.47% 3.62%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $546.0M $228.7M
YoY Change
Total Liabilities & Shareholders Equity $757.2M $363.9M
YoY Change 108.09% -12.16%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$46.68M -$41.56M
YoY Change 12.33% 48.42%
Depreciation, Depletion And Amortization $2.122M $1.860M
YoY Change 14.09% 7.51%
Cash From Operating Activities -$25.71M -$41.27M
YoY Change -37.71% 25.25%
INVESTING ACTIVITIES
Capital Expenditures $4.058M $3.876M
YoY Change 4.7% 472.53%
Acquisitions $822.0K
YoY Change
Other Investing Activities -$822.0K
YoY Change
Cash From Investing Activities -$4.880M -$3.876M
YoY Change 25.9% 34.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $28.73M
YoY Change 2744.95%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 485.0K 62.62M
YoY Change -99.23% 6099.8%
NET CHANGE
Cash From Operating Activities -25.71M -41.27M
Cash From Investing Activities -4.880M -3.876M
Cash From Financing Activities 485.0K 62.62M
Net Change In Cash -31.27M 15.85M
YoY Change -297.32% -144.3%
FREE CASH FLOW
Cash From Operating Activities -$25.71M -$41.27M
Capital Expenditures $4.058M $3.876M
Free Cash Flow -$29.77M -$45.15M
YoY Change -34.06% 34.25%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
485000
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46641448
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5897000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46298635
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.00
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46599114
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45468485
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001590560
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-36294
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
uniQure N.V.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
P7
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
Paasheuvelweg 25
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
1105 BP
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Amsterdam
CY2022Q1 dei Entity Address Country
EntityAddressCountry
NL
CY2022Q1 dei City Area Code
CityAreaCode
31
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
20-240-6000
CY2022Q1 dei Security12b Title
Security12bTitle
Ordinary Shares, par value €0.05
CY2022Q1 dei Trading Symbol
TradingSymbol
QURE
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
46647620
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
524886000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
556256000
CY2022Q1 qure Accounts Receivable And Contract With Customer Asset Current
AccountsReceivableAndContractWithCustomerAssetCurrent
38644000
CY2021Q4 qure Accounts Receivable And Contract With Customer Asset Current
AccountsReceivableAndContractWithCustomerAssetCurrent
58768000
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
12422000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10540000
CY2022Q1 qure Other Current Assets And Receivables
OtherCurrentAssetsAndReceivables
2260000
CY2021Q4 qure Other Current Assets And Receivables
OtherCurrentAssetsAndReceivables
2675000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
578212000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
628239000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
38500000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
36900000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
44918000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43505000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24941000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25573000
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
61135000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
62686000
CY2022Q1 us-gaap Goodwill
Goodwill
26565000
CY2021Q4 us-gaap Goodwill
Goodwill
27633000
CY2022Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
15442000
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
15647000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5937000
CY2022Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
178938000
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
180941000
CY2022Q1 us-gaap Assets
Assets
757150000
CY2021Q4 us-gaap Assets
Assets
809180000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
9920000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2502000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19945000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28487000
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
9081000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5754000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5774000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
44700000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
36763000
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
101421000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
100963000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28232000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28987000
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
22059000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
29542000
CY2022Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
11298000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
12913000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3439000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4236000
CY2022Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
166449000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
176641000
CY2022Q1 us-gaap Liabilities
Liabilities
211149000
CY2021Q4 us-gaap Liabilities
Liabilities
213404000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.05
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.05
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46641448
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46298635
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
2821000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2802000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1084306000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1076972000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-39306000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-28856000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-501820000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-455142000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
546001000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
595776000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
757150000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
809180000
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1792000
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
454000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45003000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32656000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10987000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12375000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
55990000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
45031000
CY2022Q1 us-gaap Other Income
OtherIncome
311000
CY2021Q1 us-gaap Other Income
OtherIncome
352000
CY2022Q1 us-gaap Other Expenses
OtherExpenses
193000
CY2021Q1 us-gaap Other Expenses
OtherExpenses
233000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-54080000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-44458000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
42000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
40000
CY2022Q1 us-gaap Interest Expense
InterestExpense
2515000
CY2021Q1 us-gaap Interest Expense
InterestExpense
1551000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
8567000
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
4626000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
692000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47294000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-41343000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-616000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
213000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-46678000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41556000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-10450000
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-7560000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-57128000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49116000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.00
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46599114
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45468485
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
243905000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41556000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-7560000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
27699000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
392000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5761000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
49000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
228690000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
595776000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-46678000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-10450000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
424000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6868000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
61000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
546001000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-46678000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-41556000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2122000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1862000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6868000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5761000
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-616000
CY2021Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
213000
CY2022Q1 qure Change In Fair Value Of Derivative Financial Instruments And Contingent Consideration
ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration
1512000
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
7356000
CY2021Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
5342000
CY2022Q1 qure Increase Decrease In Accounts Receivable And Contract Assets Prepaid Expenses And Other Current Assets And Receivables
IncreaseDecreaseInAccountsReceivableAndContractAssetsPrepaidExpensesAndOtherCurrentAssetsAndReceivables
-17209000
CY2021Q1 qure Increase Decrease In Accounts Receivable And Contract Assets Prepaid Expenses And Other Current Assets And Receivables
IncreaseDecreaseInAccountsReceivableAndContractAssetsPrepaidExpensesAndOtherCurrentAssetsAndReceivables
8023000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7306000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2510000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6078000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3302000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25711000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41273000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4058000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3876000
CY2022Q1 qure Payments To Acquire Remaining Outstanding Ordinary Shares
PaymentsToAcquireRemainingOutstandingOrdinaryShares
822000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4880000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3876000
CY2021Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
442000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28734000
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1161000
CY2021Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
34603000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
485000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
62618000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1168000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1620000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-31274000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15849000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
559353000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
247680000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
528079000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
263529000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
524886000
CY2022Q1 qure Accruals For Services Provided By Vendors Not Yet Billed Current
AccrualsForServicesProvidedByVendorsNotYetBilledCurrent
10341000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
260813000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3193000
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2716000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
528079000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
263529000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
1906000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
1410000
CY2022Q1 qure Increase Decrease In Accounts Payable And Accrued Liabilities Related To Non Current Assets
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets
-611000
CY2022Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1</b></span>General business information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">uniQure (the “Company”) was incorporated on January 9, 2012 as a private company with limited liability (<i style="font-style:italic;">besloten vennootschap met beperkte aansprakelijkheid</i>) under the laws of the Netherlands. The Company is a leader in the field of gene therapy and seeks to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. The Company’s business was founded in 1998 and was initially operated through its predecessor company, Amsterdam Molecular Therapeutics (AMT) Holding N.V (“AMT”). In 2012, AMT undertook a corporate reorganization, pursuant to which uniQure B.V. acquired the entire business and assets of AMT and completed a share-for-share exchange with the shareholders of AMT. Effective February 10, 2014, in connection with its initial public offering, the Company converted into a public company with limited liability (<i style="font-style:italic;">naamloze vennootschap</i>) and changed its legal name from uniQure B.V. to uniQure N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 1pt 0pt 1pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company is registered in the trade register of the Chamber of Commerce (<i style="font-style:italic;">Kamer van Koophandel</i>) in Amsterdam, the Netherlands under number 54385229. The Company’s headquarters are in Amsterdam, the Netherlands, and its registered office is located at Paasheuvelweg 25, Amsterdam 1105 BP, the Netherlands and its telephone number is +31 20 240 6000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s ordinary shares are listed on the Nasdaq Global Select Market and trade under the symbol “QURE”.</p>
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.3</b></span><b style="font-weight:bold;">Use of estimates </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p>
CY2021Q4 qure Accruals For Services Provided By Vendors Not Yet Billed Current
AccrualsForServicesProvidedByVendorsNotYetBilledCurrent
13012000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9604000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12603000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2872000
CY2020Q4 qure Number Of Collaboration Targets
NumberOfCollaborationTargets
4
CY2020Q4 qure Collaboration Agreement Cash Payable
CollaborationAgreementCashPayable
70000000.0
CY2020Q4 qure Collaboration Agreement Cash Payable
CollaborationAgreementCashPayable
70000000.0
CY2020Q4 qure Collaboration Agreement Cash Payable
CollaborationAgreementCashPayable
70000000.0
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
9100000
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
31100000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19945000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28487000
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
9200000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
400000
CY2021Q3 us-gaap Deferred Compensation Arrangement With Individual Requisite Service Period1
DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1
P1Y
CY2021Q4 us-gaap Deferred Compensation Arrangement With Individual Requisite Service Period1
DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1
P3Y
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.013
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.258
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.005
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6428412
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4143357

Files In Submission

Name View Source Status
0001558370-22-006570-index-headers.html Edgar Link pending
0001558370-22-006570-index.html Edgar Link pending
0001558370-22-006570.txt Edgar Link pending
0001558370-22-006570-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
qure-20220331.xsd Edgar Link pending
qure-20220331x10q.htm Edgar Link pending
qure-20220331x10q_htm.xml Edgar Link completed
qure-20220331xex31d1.htm Edgar Link pending
qure-20220331xex31d2.htm Edgar Link pending
qure-20220331xex32d1.htm Edgar Link pending
qure-20220331_cal.xml Edgar Link unprocessable
qure-20220331_def.xml Edgar Link unprocessable
qure-20220331_lab.xml Edgar Link unprocessable
qure-20220331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending